Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(3):340–346. doi: 10.1038/bjc.1997.388

Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas.

C Charpin 1, S Garcia 1, C Bouvier 1, B Devictor 1, L Andrac 1, M N Lavaut 1, C Allasia 1
PMCID: PMC2224069  PMID: 9252201

Abstract

Expression of the bcl-2 gene was investigated in 218 human breast carcinomas by immunohistochemical analysis. Immunodetections were assessed using (1) frozen sections, (2) documented commercially available monoclonal antibody (bcl-2/124, Dako), (3) automation of immunoperoxidase technique (Ventana) and (4) quantitative evaluation of results by image analysis (SAMBA) and statistical analysis of quantitative data (BMDP software). Bcl-2 protein expression was correlated with current prognostic indicators and with molecular markers detected by the same procedure as for Bcl-2. It was shown that Bcl-2 expression is not related to patients' age, tumour size and type or lymph node status, but an inverse relationship was observed between Bcl-2 and tumour grade (P < 0.0001). An inverse relationship was also observed between Bcl-2 expression and p53 (P < 0.0001), Ki67/MIB1 antigen- (P = 0.0012), and P-gp- (P = 0.002) positive immunoreactions. In contrast, anti-Bcl-2 positive reaction was significantly associated with ER-positive (P < 0.001) and with ER/PR-positive or ER/PR/pS2-positive immunoreactions (P < or = 0.005). Bcl-2 expression was independent of CD31 and cathepsin D expression. Thus, Bcl-2 protein, thought to be antiapoptotic, exhibits parodoxical expression in human breast carcinomas. It is strongly detected in low-grade tumours (well-differentiated) with low (MIB1) growth fraction, but is independent of the tumour progression (size, node status, CD31, and cathepsin D). Bcl-2 acting on apoptosis is related to p53 gene abnormalities in breast carcinomas. Bcl-2 protein expression may also be involved in response to endocrine therapy (associated to ER/PR/pS2 positive immunoreactions) and probably with chemoresistance mechanisms (inverse relationship with P-gp).

Full text

PDF
340

Images in this article

341Figure 1
on p.341
342Figure 2
on p.342

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alnemri E. S., Fernandes T. F., Haldar S., Croce C. M., Litwack G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer Res. 1992 Jan 15;52(2):491–495. [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brugal G., Garbay C., Giroud F., Adelh D. A double scanning microphotometer for image analysis: hardware, software and biomedical applications. J Histochem Cytochem. 1979 Jan;27(1):144–152. doi: 10.1177/27.1.374569. [DOI] [PubMed] [Google Scholar]
  4. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  5. Charpin C., DeVictor B., Andrac L., Amabile J., Bergeret D., LaVaut M. N., Allasia C., Piana L. p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol. 1995 Feb;26(2):159–166. doi: 10.1016/0046-8177(95)90032-2. [DOI] [PubMed] [Google Scholar]
  6. Charpin C., Devictor B., Bergeret D., Andrac L., Boulat J., Horschowski N., Lavaut M. N., Piana L. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol. 1995 Apr;103(4):443–448. doi: 10.1093/ajcp/103.4.443. [DOI] [PubMed] [Google Scholar]
  7. Charpin C., Devictor B., Bonnier P., Andrac L., Lavaut M. N., Allasia C., Piana L. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol. 1993 Aug;170(4):463–470. doi: 10.1002/path.1711700410. [DOI] [PubMed] [Google Scholar]
  8. Charpin C., Devictor B., Bonnier P., Andrac L., Lavaut M. N., Allasia C., Piana L. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol. 1993 Aug;170(4):463–470. doi: 10.1002/path.1711700410. [DOI] [PubMed] [Google Scholar]
  9. Charpin C., Jacquemier J., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast disorders. Am J Pathol. 1988 Aug;132(2):199–211. [PMC free article] [PubMed] [Google Scholar]
  10. Charpin C., Martin P. M., De Victor B., Lavaut M. N., Habib M. C., Andrac L., Toga M. Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. Cancer Res. 1988 Mar 15;48(6):1578–1586. [PubMed] [Google Scholar]
  11. Charpin C., Pellissier J. F. Marqueurs moléculaires dans les cancers du sein: aspect pratique et évaluation morphologique. Bull Acad Natl Med. 1994 Mar;178(3):475–493. [PubMed] [Google Scholar]
  12. Charpin C., Vielh P., Duffaud F., Devictor B., Andrac L., Lavaut M. N., Allasia C., Horschowski N., Piana L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst. 1994 Oct 19;86(20):1539–1545. doi: 10.1093/jnci/86.20.1539. [DOI] [PubMed] [Google Scholar]
  13. Chen-Levy Z., Cleary M. L. Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem. 1990 Mar 25;265(9):4929–4933. [PubMed] [Google Scholar]
  14. Chen-Levy Z., Nourse J., Cleary M. L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol. 1989 Feb;9(2):701–710. doi: 10.1128/mcb.9.2.701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cleary M. L., Smith S. D., Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986 Oct 10;47(1):19–28. doi: 10.1016/0092-8674(86)90362-4. [DOI] [PubMed] [Google Scholar]
  16. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990 Aug-Sep;2(8-9):275–280. [PubMed] [Google Scholar]
  17. Fisher T. C., Milner A. E., Gregory C. D., Jackman A. L., Aherne G. W., Hartley J. A., Dive C., Hickman J. A. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 1993 Jul 15;53(14):3321–3326. [PubMed] [Google Scholar]
  18. Galaktionov K., Lee A. K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D. CDC25 phosphatases as potential human oncogenes. Science. 1995 Sep 15;269(5230):1575–1577. doi: 10.1126/science.7667636. [DOI] [PubMed] [Google Scholar]
  19. Galea M. H., Blamey R. W., Elston C. E., Ellis I. O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–219. doi: 10.1007/BF01840834. [DOI] [PubMed] [Google Scholar]
  20. Gee J. M., Robertson J. F., Ellis I. O., Willsher P., McClelland R. A., Hoyle H. B., Kyme S. R., Finlay P., Blamey R. W., Nicholson R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994 Dec 1;59(5):619–628. doi: 10.1002/ijc.2910590508. [DOI] [PubMed] [Google Scholar]
  21. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994 Apr 15;54(8):2095–2097. [PubMed] [Google Scholar]
  22. Hellemans P., van Dam P. A., Weyler J., van Oosterom A. T., Buytaert P., Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995 Aug;72(2):354–360. doi: 10.1038/bjc.1995.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hockenbery D., Nuñez G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22;348(6299):334–336. doi: 10.1038/348334a0. [DOI] [PubMed] [Google Scholar]
  24. Johnston S. R., MacLennan K. A., Sacks N. P., Salter J., Smith I. E., Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer. 1994;30A(11):1663–1669. doi: 10.1016/0959-8049(94)00327-2. [DOI] [PubMed] [Google Scholar]
  25. Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992 Aug 15;80(4):879–886. [PubMed] [Google Scholar]
  26. Krajewski S., Tanaka S., Takayama S., Schibler M. J., Fenton W., Reed J. C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993 Oct 1;53(19):4701–4714. [PubMed] [Google Scholar]
  27. Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F., Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989 Nov 1;64(9):1914–1921. doi: 10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  28. Leek R. D., Kaklamanis L., Pezzella F., Gatter K. C., Harris A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer. 1994 Jan;69(1):135–139. doi: 10.1038/bjc.1994.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lotem J., Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993 Jan;4(1):41–47. [PubMed] [Google Scholar]
  30. Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993 Jan 1;81(1):151–157. [PubMed] [Google Scholar]
  31. Miyashita T., Reed J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992 Oct 1;52(19):5407–5411. [PubMed] [Google Scholar]
  32. Nathan B., Gusterson B., Jadayel D., O'Hare M., Anbazhagan R., Jayatilake H., Ebbs S., Micklem K., Price K., Gelber R. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1994 May;5(5):409–414. doi: 10.1093/oxfordjournals.annonc.a058871. [DOI] [PubMed] [Google Scholar]
  33. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 1993 Jul 1;82(1):15–21. [PubMed] [Google Scholar]
  34. Siegel R. M., Katsumata M., Miyashita T., Louie D. C., Greene M. I., Reed J. C. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7003–7007. doi: 10.1073/pnas.89.15.7003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  36. Tsujimoto Y., Cossman J., Jaffe E., Croce C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985 Jun 21;228(4706):1440–1443. doi: 10.1126/science.3874430. [DOI] [PubMed] [Google Scholar]
  37. Tsujimoto Y., Croce C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214–5218. doi: 10.1073/pnas.83.14.5214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vaux D. L., Cory S., Adams J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988 Sep 29;335(6189):440–442. doi: 10.1038/335440a0. [DOI] [PubMed] [Google Scholar]
  39. Wyllie A. H. Apoptosis: cell death in tissue regulation. J Pathol. 1987 Dec;153(4):313–316. doi: 10.1002/path.1711530404. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES